As a world-leading service provider of antibody development and engineering, Creative Biolabs has combined artificial intelligence, big data, and machine learning to generate a novel artificial intelligence (AI)-powered computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates. This platform has been considered as an attractive strategy for producing human antibodies with high specificity and affinity.
Creative Biolabs offers antibody development and production services with different antibody formats (Fab, scFv) and flexible strategies (hybridoma, phage display, B lymphocytes sorting). In addition, AI technology can help us discover diverse and rare antibodies.
Why Choose AI?
- AI can typically generate 10 times more antibody sequence clusters than a laboratory-based approach alone.
- AI expands the diversity that leads to the discovery of new binding modalities and potentially new therapeutic modes-of-action.
- AI creates optimized antibody sequences to increase the success rate.
- AI helps CROs to become more competitive by increasing the hits, diversity, and delivery speed.
